Newron Pharmaceuticals SpA (NWRN) - Total Liabilities
Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) has total liabilities worth CHF51.15 Million CHF (≈ $64.67 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Newron Pharmaceuticals SpA - Total Liabilities Trend (2005–2025)
This chart illustrates how Newron Pharmaceuticals SpA's total liabilities have evolved over time, based on quarterly financial data. See Newron Pharmaceuticals SpA working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Newron Pharmaceuticals SpA Competitors by Total Liabilities
The table below lists competitors of Newron Pharmaceuticals SpA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dalmia Bharat Sugar and Industries Limited
NSE:DALMIASUG
|
India | Rs22.86 Billion |
|
Fabryka Farb i Lakierów ŚNIEŻKA SA
WAR:SKA
|
Poland | zł289.79 Million |
|
Shandong Teamgene Technology Co. Ltd. A
SHG:603151
|
China | CN¥1.48 Billion |
|
Shanghai Kaichuang Marine International Co Ltd
SHG:600097
|
China | CN¥1.05 Billion |
|
Duopharma Biotech Bhd
KLSE:7148
|
Malaysia | RM689.10 Million |
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
USA | $123.85 Million |
|
Nivika Fastigheter AB Series B
ST:NIVI-B
|
Sweden | Skr8.71 Billion |
|
Provident Agro Tbk
JK:PALM
|
Indonesia | Rp4.70 Trillion |
Liability Composition Analysis (2005–2025)
This chart breaks down Newron Pharmaceuticals SpA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Newron Pharmaceuticals SpA (NWRN) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Newron Pharmaceuticals SpA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Newron Pharmaceuticals SpA (2005–2025)
The table below shows the annual total liabilities of Newron Pharmaceuticals SpA from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF51.15 Million ≈ $64.67 Million |
-18.09% |
| 2024-12-31 | CHF62.45 Million ≈ $78.95 Million |
+11.97% |
| 2023-12-31 | CHF55.77 Million ≈ $70.51 Million |
+8.88% |
| 2022-12-31 | CHF51.23 Million ≈ $64.76 Million |
+8.12% |
| 2021-12-31 | CHF47.38 Million ≈ $59.90 Million |
+39.55% |
| 2020-12-31 | CHF33.95 Million ≈ $42.92 Million |
+44.54% |
| 2019-12-31 | CHF23.49 Million ≈ $29.70 Million |
+354.97% |
| 2018-12-31 | CHF5.16 Million ≈ $6.53 Million |
-2.64% |
| 2017-12-31 | CHF5.30 Million ≈ $6.70 Million |
-22.52% |
| 2016-12-31 | CHF6.84 Million ≈ $8.65 Million |
-5.83% |
| 2015-12-31 | CHF7.27 Million ≈ $9.19 Million |
-6.98% |
| 2014-12-31 | CHF7.81 Million ≈ $9.88 Million |
-25.79% |
| 2013-12-31 | CHF10.53 Million ≈ $13.31 Million |
-38.21% |
| 2012-12-31 | CHF17.04 Million ≈ $21.54 Million |
+144.08% |
| 2011-12-31 | CHF6.98 Million ≈ $8.83 Million |
+0.58% |
| 2010-12-31 | CHF6.94 Million ≈ $8.78 Million |
-44.00% |
| 2009-12-31 | CHF12.39 Million ≈ $15.67 Million |
-15.85% |
| 2008-12-31 | CHF14.73 Million ≈ $18.62 Million |
+13.58% |
| 2007-12-31 | CHF12.97 Million ≈ $16.40 Million |
-29.13% |
| 2006-12-31 | CHF18.30 Million ≈ $23.13 Million |
+182.52% |
| 2005-12-31 | CHF6.48 Million ≈ $8.19 Million |
-- |
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more